Search results for "PC(O)"

showing 10 items of 172 documents

Prevalence and metabolic characteristics of adrenal androgen excess in hyperandrogenic women with different phenotypes

2007

Background: Serum DHEAS has been found to be elevated in some women with polycystic ovary syndrome (PCOS). We wished to determine whether this prevalence is different in women with androgen excess who have different phenotypes and to correlate these findings with various cardiovascular and metabolic parameters. Methods: Two hundred and thirty-eight young hyperandrogenic women categorized into various diagnostic groups were evaluated for elevations in serum DHEAS, testosterone, glucose, insulin, quantitative insulin-sensitivity check index (QUICKI), cholesterol, HDL-C, LDL-C, triglycerides and C-reactive protein (CRP). Data were stratified based on elevations in DHEAS. Results: Serum DHEAS w…

Adultmedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentAndrogen Excesschemistry.chemical_compoundEndocrinologyInternal medicinePrevalenceHumansInsulinMedicineTestosteroneTestosteronebusiness.industryCholesterolInsulinPolycystic ovary syndrome (PCOS)Hyperandrogenismnutritional and metabolic diseasesmedicine.diseasePhenotypePolycystic ovaryPhenotypeEndocrinologychemistryAdrenal CortexAndrogensFemaleHyperandrogenismbusinessPolycystic Ovary SyndromeJournal of Endocrinological Investigation
researchProduct

Uterine effects of metformin administration in anovulatory women with polycystic ovary sindrome

2006

Background Metformin has been shown to improve fertility in anovulatory patients with polycystic ovary syndrome (PCOS), inducing not only a high ovulation and pregnancy rate but also reducing the incidence of miscarriages. The aim of the present study was to evaluate the uterine effects of metformin in patients with PCOS who ovulated under metformin. Methods Thirty-seven non-obese primary infertile anovulatory patients with PCOS and another 30 age- and body mass index-matched healthy women (control group) were studied. PCOS patients were treated with metformin (850 mg twice daily) for 6 months, whereas the control group did not receive any treatment. In these PCOS patients who ovulated whil…

Adultmedicine.medical_specialtyendocrine system diseasesPhysiologymedia_common.quotation_subjectUterusEndometriumFertility AgentsAnovulationEndometriumanovulation; endometrium; metforminMenstruation-Inducing AgentUltrasoundmedicinePCOSHumansOvulationFertility Agentmedia_commonGynecologyMenstruation-Inducing Agentsbusiness.industryRehabilitationUterusanovulation endometrium metformin PCOS ultrasoundnutritional and metabolic diseasesObstetrics and Gynecologymedicine.diseasePolycystic ovaryfemale genital diseases and pregnancy complicationsMetforminMetforminPregnancy ratemedicine.anatomical_structureUteruReproductive MedicineIn uteroRegional Blood FlowFemalebusinessmedicine.drugAnovulationHumanPolycystic Ovary SyndromeDevelopmental Biology
researchProduct

Uterine effects of clomiphene citrate in women with polycystic ovary syndrome: a prospective controlled study

2006

Background Previous data on the efficacy of clomiphene citrate, the most commonly used drug for treating anovulatory infertility in patients with polycystic ovary syndrome (PCOS), have shown a discrepancy between ovulation and pregnancy rates. In the present subanalysis (of a larger previously published randomized controlled trial), the effect of clomiphene citrate on several ultrasonographic markers of uterine receptivity in PCOS patients who ovulated under treatment was studied. Methods Thirty-three PCOS women who ovulated under 150 mg daily clomiphene citrate and 33 healthy controls were studied. Uterine, subendometrial and endometrial blood flows, endometrial thickness and pattern were …

Adultmedicine.medical_specialtymedia_common.quotation_subjectEarly Pregnancy LossUterusanovulation; clomiphene citrate; Doppler; PCOS; velocimetryBiologyClomiphenelaw.inventionAnovulationRandomized controlled trialPregnancyReference ValueslawClomifeneclomiphene citratemedicinePCOSHumansOvulationUltrasonographymedia_commonGynecologyPregnancyvelocimetryObstetricsRehabilitationEstrogen AntagonistsPregnancy OutcomeDopplerObstetrics and GynecologyGenitalia Femalemedicine.diseasePolycystic ovaryTreatment Outcomemedicine.anatomical_structureReproductive Medicinepolycystic ovary syndromeanovulationFemalemedicine.drug
researchProduct

No phenotypic differences for polycystic ovary syndrome (PCOS) between women with and without type 1 diabetes mellitus.

2013

Context: Women with type 1 diabetes mellitus (DM1) have a higher prevalence of polycystic ovary syndrome (PCOS) than the general population. Objective: The aim of this study was to clarify, in DM1 women with PCOS(PCOS-DM1), the influence of insulin therapy and glycemic control and evaluate the hormonal and phenotypic differences with age-matched and body mass index (BMI)-matched women with PCOS without diabetes. Design, Setting, and Patients: We evaluated 103 DM1 women with and without PCOS treated with intensive insulin therapy; 38 age-matched and BMI-matched women with PCOS without diabetes were compared in a cross-sectional study. Outcome Measurements: Clinical, anthropometric, and metab…

Adultmusculoskeletal diseasesPCOS Type 1 Diabetescongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyAdolescentendocrine system diseasesEndocrinology Diabetes and Metabolismmedia_common.quotation_subjectClinical BiochemistryPopulationContext (language use)BiochemistryBody Mass IndexSettore MED/13 - EndocrinologiaYoung AdultEndocrinologyInternal medicineDiabetes mellitusPrevalencemedicineHumanseducationReproductive HistoryMenstrual cyclemedia_commoneducation.field_of_studyType 1 diabetesbusiness.industryPolycystic ovary syndrome (PCOS)Biochemistry (medical)nutritional and metabolic diseasesmedicine.diseasePolycystic ovaryfemale genital diseases and pregnancy complicationsCross-Sectional StudiesDiabetes Mellitus Type 1PhenotypeEndocrinologyCase-Control StudiesFemalebusinessBody mass indexPolycystic Ovary Syndrome
researchProduct

Purely organic Vis-to-UV upconversion with an excited annihilator singlet beyond 4 eV

2022

The conversion of visible light into high-energy UV photons via sensitized triplet–triplet annihilation (TTA-UC) could pave the way for several energy-demanding applications. However, only a handful of annihilator chromophores for Vis-to-UV upconversion are known and the current limit for the excited-state energy of the UV emitter in TTA-UC schemes is below 4 eV, i.e., in the spectral region (>310 nm) where the sun still provides a considerable photon flux. Herein, we present a novel biphenyl-based annihilator with a highly fluorescent singlet state at 4.04 eV. This annihilator can be combined with a widely-used TADF sensitizer to yield an efficient blue-light (2.77 eV) driven upconversion …

AnnihilatorMaterials sciencePhotonExcited stateMaterials ChemistryGeneral ChemistrySinglet stateChromophoreAtomic physicsFluorescencePhoton upconversionVisible spectrumJournal of Materials Chemistry C
researchProduct

Mullarian-inhibiting substance reflects ovarian findings in women with polycystic ovary syndrome better than does inhibin-B

2005

Objective: To investigate Müllerian-inhibiting substance (MIS) levels in women with polycystic ovary syndrome (PCOS), as well as relationships to ovarian morphology, levels of inhibin B, and other reproductive hormones. Design: Prospective clinical study. Setting: Academic endocrinology centers in Palermo, Italy and New York. Patient(s): Forty-six women with PCOS, recruited on the basis of the classic criteria of chronic anovulation and hyperandrogenism, and 25 age-matched ovulatory controls. Intervention(s): Fasting blood was obtained in all subjects in the early follicular phase (days 5–6) after spontaneous or induced menses (in PCOS), and transvaginal ultrasounds were performed. Main Out…

Anti-Mullerian Hormoneendocrine systemmedicine.medical_specialtyendocrine system diseasesmedicine.medical_treatmentAnovulationPCOS MIS inhibin B ovarian volume insulinInternal medicinemedicineHumansInsulinInhibinsObesityProspective StudiesAndrostenedioneTestosteroneGlycoproteinsUltrasonographybusiness.industryInsulinOvaryHyperandrogenismObstetrics and Gynecologymedicine.diseasePolycystic ovaryfemale genital diseases and pregnancy complicationsTesticular HormonesEndocrinologyFollicular PhaseReproductive MedicineFemalebusinessLuteinizing hormoneBody mass indexBiomarkersAnovulationPolycystic Ovary Syndrome
researchProduct

Arterial and mixed venous blood gas status during apnoea of intubation--proof of the Christiansen-Douglas-Haldane effect in vivo.

1989

The Christiansen-Douglas-Haldane effect, in short the Haldane effect, describes the dependence of the CO2 binding of blood on the degree of oxygenation of haemoglobin. Under the physiological conditions of an ‘open’ system between blood and alveoli the partial pressure of arterial C02 (PaCO2), must be less than that of mixed venous blood (P[Formula: see text]CO2). During the unphysiological conditions of a ‘closed’ system, e.g. hyperoxic apnoea, i.e. continuous oxygen uptake without CO2 delivery by the lungs, the Paco2 will not only approximate the P[Formula: see text]CO2 but will even exceed it. Without the Haldane effect, rapid adjustment of Paco2 to P[Formula: see text]CO2 would be expe…

Apneamedicine.medical_treatmentPartial PressureCritical Care and Intensive Care MedicinepCO2VeinsExcretionIn vivoHaldane effectmedicineIntubation IntratrachealIntubationHumansLungbusiness.industryApneaOxygenationArteriesCarbon DioxideHydrogen-Ion ConcentrationAnesthesiology and Pain Medicinemedicine.anatomical_structureAnesthesiaOxyhemoglobinsGasesmedicine.symptombusinessAnaesthesia and intensive care
researchProduct

La diminuzione di espressione di Hsp60 e Hsp10 è associata a carcinogenesi epiteliale bronchiale in fumatori con BPCO

2006

BPCO Hsp60 Hsp10
researchProduct

MECCANISMI DI INVECCHIAMENTO DELLE CELLULE EPITELIALI DELLE VIE AEREE

BPCO fumo di sigaretta stress ossidativo senescenza
researchProduct

Occupational therapy, degree of disability and quality of life in COPD inpatients undergoing pulmonary rehabilitation programs

2010

BPCOSettore MED/10 - Malattie Dell'Apparato Respiratorio
researchProduct